Peterson Amy C.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
CTMX to Present at September Investor Conferences. CytomX Therapeutics announced it will present at upcoming investor conferences in September, a routine corporate event where biotech firms typically discuss pipeline progress and business strategy with institutional investors and analysts. The company's shares have been trading in a notably wide range over the past year, between $1.90 and $8.21, reflecting the volatility common among smaller biotechnology companies working to advance their drug candidates through development. The September conference presentations could provide updated information on CytomX's ongoing programs and corporate priorities.
Transaction History
| EXEL | ▲ Buy | Option Exercise | 40,000 | $870K | 5/16/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 72,776 | $3.3M | 5/16/2025 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 8,303 | $371K | 5/15/2025 | View on chart |
| EXEL | ▲ Buy | Grant | 159,383 | $0 | 3/31/2025 | View on chart |
| EXEL | ▲ Buy | Grant | 52,192 | $0 | 2/26/2025 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 27,224 | $954K | 11/15/2024 | View on chart |
| EXEL | ▲ Buy | Grant | 82,121 | $0 | 2/23/2024 | View on chart |
| EXEL | ▲ Buy | Grant | 240,000 | $0 | 8/24/2023 | View on chart |
| CTMX | ▼ Sell | Open Market | 4,257 | $8K | 3/16/2023 | View on chart |
| CTMX | ▼ Sell | Open Market | 7,463 | $11K | 7/20/2022 | View on chart |
| CTMX | ▲ Buy | Grant | 20,000 | $0 | 7/19/2022 | View on chart |
| CTMX | ▲ Buy | Grant | 40,000 | $0 | 2/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Exelixis Shares Rise on CABOMETYX Revenue
Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.
Exelixis Shares Rise on CABOMETYX Revenue. Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.